ArticleEndocrine oncology (Bristol, England)2025
Oral cancer cells secrete stress neurotransmitter and proliferate in response to tobacco carcinogen NNK.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma-activated medium induces apoptosis of oral squamous cell carcinoma through the MAPKs pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although there is a growing body of evidence showing the effects of stress-related catecholamines on oral cancer progression, to date there are no studies that have investigated whether oral squamous cell carcinoma (OSCC) cells can produce these hormones and whether this phenomenon is modulated by tobacco-related nitrosamines. Methods: In this study, we investigated whether keratinocytes (HaCaT) and OSCC-derived cell lines (SSC9 and SCC25) can secrete the neurotransmitter norepinephrine, as well as the effects of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on norepinephrine secretion and OSCC proliferation. Results: Supernatant from the HaCaT, SCC9 and SCC25 cells showed higher norepinephrine levels (6-, 14.9- and 15.1-fold higher, respectively) compared to the culture medium without cells. When the cells were stimulated with NNK, a tobacco-specific carcinogen, there was an increase in the levels of norepinephrine secretion by HaCaT and SCC25 cells but not by SCC9 cells. NNK (10 μM) induced cell proliferation in the HaCaT, SCC9 and SCC25 cell lines, and these effects were totally inhibited by blocking β-adrenergic receptors with propranolol. The NNK-induced OSCC cell proliferation was furthermore dependent on the activation of nicotinic acetylcholine receptors α4 (nAChR-α4) (completely in SCC9 cells and partially in SCC25 cells) but not on the activation of nAChR-α7. Inhibition of the β-adrenergic receptors, nAChR-α4 and nAChR-α7 did not block NNK-induced HaCaT proliferation. Conclusion: Our findings suggest that oral cancer cells secrete the neurotransmitter norepinephrine and that the tobacco nitrosamine NNK promotes increased cell proliferation through a stress-related cellular adrenergic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.